We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Signaturefd LLC increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 357.2% during the 4th ...

Apellis Pharmaceuticals Inc. will escape an investor lawsuit alleging it concealed safety risks connected to its ...

In a report released on March 21, Umer Raffat from Evercore ISI maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report).

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Morgan Stanley analyst Judah Frommer notes that Novartis (NVS) has received FDA approval for Fabhalta for C3G. The label comes with a few important restrictions/caveats that leave room for Apellis’s ...

Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – ...

Apellis Pharmaceuticals reported strong financial results for the full year 2024, with total revenues reaching $781.4 million, a 97% increase from the previous year, primarily driven by SYFOVRE ...

JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with ...

During a quarterly conference call, as Apellis Pharmaceuticals discussed its plan to increase sales of GA treatment Syfovre, it stressed the importance of attracting more patients to the market ...

In this article, we are going to look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market ...